




RealRate

PHARMACEUTICAL 2021

Bellerophon Therapeutics Inc.
Rank 240 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Bellerophon Therapeutics Inc. Rank 240 of 409

The relative strengths and weaknesses of Bellerophon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 155% points. The greatest weakness of Bellerophon Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is -187%, being 167% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	48,080
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,433
Liabilities, Non-Current	956
Other Assets	1,990
Other Compr. Net Income	0
Other Expenses	-1,798
Other Liabilities	601
Other Net Income	-250
Property and Equipment	169
Research and Development	17,890
Revenues	0
Selling, General and Administrative Expense	8,386

Output Variable	Value in 1000 USD
Assets	50,239
Liabilities	11,990
Expenses	24,478
Stockholders Equity	38,249
Net Income	-24,728
Comprehensive Net Income	-24,728
Economic Capital Ratio	-187%

